Kamada (KMDA) SEC Filings: History & Chart

Kamada Ltd.(KMDA)

Drug Manufacturers - Specialty & Generic · Rehovot, HM

$8.15+0.15 (+1.89%)

Delayed quote: Oct 6, 2026, 3:14 PM EDT

About Kamada Ltd.

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Rehovot, HM

462 employees

www.kamada.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Amir London

View full financials

Form	Filing Date	Accepted	Document
6-K	Oct 6, 2026	Oct 6, 2026	View filing
6-K	Oct 5, 2026	Oct 5, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 25, 2026	Sep 25, 2026	View filing
4	Sep 24, 2026	Sep 24, 2026	View filing
4	Sep 24, 2026	Sep 24, 2026	View filing
4	Sep 24, 2026	Sep 24, 2026	View filing
4	Sep 24, 2026	Sep 24, 2026	View filing
4	Sep 24, 2026	Sep 24, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 17, 2026	Sep 17, 2026	View filing
4	Sep 17, 2026	Sep 17, 2026	View filing
4	Sep 17, 2026	Sep 17, 2026	View filing
6-K	Sep 17, 2026	Sep 17, 2026	View filing
EFFECT	Sep 15, 2026	Sep 16, 2026	View filing
4	Sep 11, 2026	Sep 11, 2026	View filing
6-K	Sep 10, 2026	Sep 10, 2026	View filing
F-3	Sep 9, 2026	Sep 9, 2026	View filing
4	Sep 8, 2026	Sep 8, 2026	View filing

SEC Filings

Recent Filings